Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases

ZHU Ji-ying; QIN Bai-yan; WANG Ming-xian; FENG Jia-fu; JIANG Yu

doi:10.13422/j.cnki.syfjx.2014140188

您当前的位置：

首页 >

文章列表页 >

Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases

更新时间：2024-01-04

- Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 14, Pages: 188-192(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014140188
  CLC： R259
- Published：2014
- 稿件说明：
移动端阅览
ZHU Ji-ying, QIN Bai-yan, WANG Ming-xian, et al. Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(14): 188-192.
DOI：

ZHU Ji-ying, QIN Bai-yan, WANG Ming-xian, et al. Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(14): 188-192. DOI： 10.13422/j.cnki.syfjx.2014140188.

摘要

目的：观察疏肝健脾方对糖尿病前期患者糖代谢、脂代谢的调节作用及对炎性因子的影响。方法： 91例糖尿病前期患者随机按就诊顺序分为对照组45例和观察组46例。对照组服用吡格列酮二甲双胍片，1片/次，2次/d。观察组服用疏肝健脾方，1剂/d。两组疗程均为12周。测量治疗后体重、腰围；检测治疗前后血脂水平，包括甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）及低密度脂蛋白胆固醇（LDL-C）；检测治疗前后空腹血糖（FBG）、空腹胰岛素（FINS）、餐后2 h血糖（2 hPG）及糖化血红蛋白（HbAlc），计算体重指数（BMI）、胰岛素抵抗指数（HOMA-IR）、胰岛β细胞分泌功能指数（HOMA-IS）和胰岛素敏感指数（ISI）；检测治疗前后血清脂联素（APN）、白细胞介素（IL-6）和超敏C-反应蛋白（hs-CRP）水平。结果：治疗后两组腰围和BMI均较治疗前下降，组间比较差异无统计学意义，治疗后两组体重均呈下降趋势；观察组FBG，2 hPG，HbA1c及FINS水平低于对照组（P<0.05或P<0.01）；观察组HOMA-IR低于对照组（P<0.01），HOMA-IS和ISI高于对照组（P<0.01）；观察组TC，TG，LDL-C和HDL-C单项指标转为正常例数多于对照组（P<0.01）；观察组血清APN高于对照组（P<0.01），观察组IL-6和hs-CRP水平低于对照组（P<0.01）。结论：疏肝健脾方能调节糖尿病前期患者的糖代谢、脂代谢，延缓或逆转其进展为糖尿病的速度，其作用机制可能与调节APN，IL-6及hs-CRP等因子有关。

Abstract

Objective: Observe regulating effect of Shugan Jianpi decoction to patients' glucose metabolism and lipid metabolism in treating early-stage diabetes and influence to inflammatory factor. Method: Ninety-one patients with early-stage diabetes were randomly divided into control group (45 cases) and observation group (46 cases)according to registration order.Patients in control group received pioglitazone hydrochloride and metformin hydrochloride tablets

1 tablet/time

2 times/day

taken orally.Patients in observation group received Shugan Jianpi decoction

1 dose/day.Course of treatment in two groups were both 12 weeks.After treatment

patients' weight and waist were measured.and levels of blood lipid was detected which including triglyceride(TG)

total cholesterol(TC)

high-density lipoprotein(HDL-C) and low density lipoprotein(LDL-C).Before and after treatment

fasting blood-glucose(FBG)

fasting insulin(FINS)

2 hours postprandial blood glucose(2 hPG) and glycosylated hemoglobin(HbAlc) were detected.body mass index(BMI)

homeostasis model assessment-insulin resistance index(HOMA-IR) of insulin

homeostasis model assessment-insulin secretion of pancreatic β-cell and insulin sensitivity index(ISI) were detected.and levels of adiponectin(APN)

interleukin-6(IL-6) and high-sensitivity c-reactive protein(hs-CRP) were also detected. Result: After treatment

compared with the time before treatment

waist and BMI in two groups decreased

which means no statistical significance from the differences between two groups

and there was a decreasing tendency of patients' weight.Levels of FBG

2 hPG

HbA1c and FINS in observation group were lower than those in control group(P<0.05 or P<0.01).HOMA-IR in observation group was lower than in control group(P<0.01) and HOMA-IS and ISI were higher than those in control group(P<0.01).Cases of turning normal of TC

LDL-C and HDL-C in observation group were more than those in control group(P<0.01).Serous APN in observation group was higher than in control group(P<0.01)

and levels of IL-6 and hs-CRP in observation group were lower than those in control group(P<0.01). Conclusion: Shugan Jianpi decoction can regulate patients' glucose metabolism and lipid metabolism in treating early-stage diabetes

and prolong or reversion speed of early-stage diabetes turning into diabetes

its mechanism of action may be related to regulating APN

IL-6 and hs-CRP and reducing chronic inflammatory reaction.

关键词

Keywords

references

Views

233

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigation of Relationship Between Spleen and Alzheimer' s Disease Based on Glucose, Lipid and Energy Metabolisms

Clinical Efficacy of Wumeiwan Combined with Bazhentang in Treatment of Obese of Type 2 Diabetes Mellitus Patients with Qi and Yin Deficiencies, Phlegm and Stasis

Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy

Mechanism of Aconiti Lateralis Radix Praeparata in Regulating Liver Lipid Metabolism in Yang-deficient Mice via PKA/PPARα/CPT1α Pathway

Gastric Cancer Intervention by Traditional Chinese Medicine Regulating Metabolic Reprogramming： A Review

Related Author

Qin ZHENG

Jun LUO

De-lin ZHANG

Yu TANG

Mei-fang ZHU

Dan-feng TANG

Hai-xia WU

Yuan-yuan GUO

Related Institution

State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Key Laboratory of Modern Chinese Medicine Preparations, Ministry of Education, Jiangxi University of Traditional Chinese Medicine

Guangxi University of Chinese Medicine

The First Affiliated Hospital of Guangxi University of Chinese Medicine

School of Traditional Chinese Medicine， Beijing University of Chinese Medicine

School of Chinese Materia Medica， Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰